A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
NCT ID: NCT04504448
Last Updated: 2022-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
45 participants
INTERVENTIONAL
2020-08-11
2021-07-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ONO-7746 Study in Healthy Adult Subject
NCT01106664
HS-10542 Study in Healthy Participants
NCT07040046
A Study of HS-10501 Tablets in Healthy Subjects
NCT06359600
Study of IPG1094 in Healthy Participants
NCT05112159
A Study to Evaluate the Food Effect on RNK08954 in Healthy Participants, and the Mass Balance Study of [14C]RNK08954 in Healthy Adult Male Subjects
NCT07334262
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HNC664 capsules
HNC664 capsules,single ascending doses Single dose
HNC664 capsules Single dose
HNC664 capsules,single ascending doses Single dose, PO,starting dose of 40mg escalating up to 500mg
HNC664 placebos
HNC664 placebos,single ascending doses Single dose
HNC664 placebos Single dose
HNC664 placebos single ascending doses,PO,Single dose, matching placebo
HNC664 capsules FED
HNC664 capsules,food effect,Single dose
HNC664 capsules FED
HNC664 capsules,single doses Single dose, PO,food effect（dosage will be based on data from SAD cohorts and decided by the IDRC）
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HNC664 capsules Single dose
HNC664 capsules,single ascending doses Single dose, PO,starting dose of 40mg escalating up to 500mg
HNC664 placebos Single dose
HNC664 placebos single ascending doses,PO,Single dose, matching placebo
HNC664 capsules FED
HNC664 capsules,single doses Single dose, PO,food effect（dosage will be based on data from SAD cohorts and decided by the IDRC）
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 18-32 kg/m2,and body weight not less than 50.0kg.
Exclusion Criteria
* Drug or alcohol abuse
* Smoking
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou Henovcom Bioscience Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pharmaron
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HNC664-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.